Search hospitals > Maryland > Baltimore
University of Maryland/Greenebaum Cancer Center
Claim this profileBaltimore, Maryland 21201
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Cancer
Conducts research for Leukemia
Conducts research for Lymphoma
671 reported clinical trials
30 medical researchers
Summary
University of Maryland/Greenebaum Cancer Center is a medical facility located in Baltimore, Maryland. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Leukemia, Lymphoma and other specialties. University of Maryland/Greenebaum Cancer Center is involved with conducting 671 clinical trials across 534 conditions. There are 30 research doctors associated with this hospital, such as Ranee Mehra, MD, Mark Mishra, MD, Teresa A. York, and Katherine Scilla, MD.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
ER positive
HER2 negative
Top PIs
Ranee Mehra, MDUniversity of Maryland/Greenebaum Cancer Center6 years of reported clinical research
Expert in Squamous Cell Carcinoma
Studies Cancer
29 reported clinical trials
56 drugs studied
Mark Mishra, MDUniversity of Maryland/Greenebaum Cancer Center8 years of reported clinical research
Studies Brain Tumor
Studies Glioblastoma
21 reported clinical trials
46 drugs studied
Teresa A. YorkUniversity of Maryland/Greenebaum Cancer Center8 years of reported clinical research
Studies Cancer
Studies Neuroblastoma
20 reported clinical trials
62 drugs studied
Katherine Scilla, MDUniversity of Maryland/Greenebaum Cancer Center11 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
20 drugs studied
Clinical Trials running at University of Maryland/Greenebaum Cancer Center
Lung Cancer
Breast Cancer
Breast cancer
Cancer
Oropharyngeal Carcinoma
Laryngeal Cancer
Ovarian Cancer
Throat Cancer
Prostate Cancer
Laryngeal Squamous Cell Carcinoma
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Thoracotomy vs Thoracoscopy
for Metastatic Osteosarcoma
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastases). Open thoracic surgery is a type of surgery done through a single larger incision (like a large cut) that goes between the ribs, opens up the chest, and removes the cancer. Thoracoscopy is a type of chest surgery where the doctor makes several small incisions and uses a small camera to help with removing the cancer. This trial is being done evaluate the two different surgery methods for patients with osteosarcoma that has spread to the lung to find out which is better.
Recruiting2 awards Phase 37 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Maryland/Greenebaum Cancer Center?
University of Maryland/Greenebaum Cancer Center is a medical facility located in Baltimore, Maryland. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Leukemia, Lymphoma and other specialties. University of Maryland/Greenebaum Cancer Center is involved with conducting 671 clinical trials across 534 conditions. There are 30 research doctors associated with this hospital, such as Ranee Mehra, MD, Mark Mishra, MD, Teresa A. York, and Katherine Scilla, MD.
Where is University of Maryland/Greenebaum Cancer Center located?
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, situated at 22 S Greene St, Baltimore, MD 21201, is a key component of the University of Maryland Medical System. It provides outpatient care in the Roslyn and Leonard Stoler Pavilion, conveniently located inside the main hospital lobby. For new patient appointments, contact 410-328-7904 or 1-800-888-8823.
Who should I call to ask about financial aid or insurance network?
**University of Maryland/Greenebaum Cancer Center Financial and Insurance Assistance:**
- For financial assistance, visit the University of Maryland Faculty Physicians, Inc. financial assistance page.
- For insurance inquiries, contact the University of Maryland Medical System's Patient Assistance Line at 410-328-7609.
- For assistance with insurance and billing questions, call the Health Center staff at 301-314-8147.
What insurance does University of Maryland/Greenebaum Cancer Center accept?
The University of Maryland/Greenebaum Cancer Center accepts a wide range of insurance plans, including commercial health insurance, Medicaid, and Medicare. It is in network with Aetna, Blue Cross Blue Shield (excluding Omnia Silver), Carefirst, United Health Care, and Cigna's PPO and Open Access Plus products. Patients are encouraged to verify coverage with their insurance company before visiting, as certain services like x-ray and in-house laboratory services may not be covered under specific plans such as Maryland Medicaid and Carefirst Blue Choice.
What awards or recognition has University of Maryland/Greenebaum Cancer Center received?
The University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCCC) is nationally recognized for its excellence in cancer treatment and research, holding a "comprehensive" designation from the National Cancer Institute (NCI). This places UMGCCC among the elite cancer centers in the United States, focusing on hormone responsive cancers, tumor immunology and immunotherapy, molecular and structural biology, and population science. Additionally, it is recognized as a Center of Excellence by various health insurance companies and national transplant networks for meeting or exceeding quality of care and patient survival benchmarks.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.